Clinical Trial Update: Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation [Phase 2]

View source ↗

Summary

Phase 2 trial of osimertinib for locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Locally Advanced or Metastatic NSCLC | Phase 2 | Status: COMPLETED | Results posted: 2025-02-11